(Q29039802)

3 March 2018

title

Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms (English)

1 reference

3 March 2018

8

A D Viny

1 reference

DOI.org query endpoint

27 March 2017

23

T Haferlach

1 reference

3 March 2018

PMC publication ID

5821256

Jaroslaw P. Maciejewski

24

object named as

J P Maciejewski

0 references

author name string

R J Molenaar

1

1 reference

3 March 2018

S Thota

2

1 reference

3 March 2018

Y Nagata

3

1 reference

3 March 2018

B Patel

4

1 reference

3 March 2018

M Clemente

5

1 reference

3 March 2018

B Przychodzen

6

1 reference

3 March 2018

C Hirsh

7

1 reference

3 March 2018

N Hosano

9

1 reference

3 March 2018

F E Bleeker

10

1 reference

3 March 2018

M Meggendorfer

11

1 reference

3 March 2018

T Alpermann

12

1 reference

3 March 2018

Y Shiraishi

13

1 reference

3 March 2018

K Chiba

14

1 reference

3 March 2018

H Tanaka

15

1 reference

3 March 2018

C J F van Noorden

16

1 reference

3 March 2018

T Radivoyevitch

17

1 reference

3 March 2018

H E Carraway

18

1 reference

3 March 2018

H Makishima

19

1 reference

3 March 2018

S Miyano

20

1 reference

3 March 2018

M A Sekeres

21

1 reference

3 March 2018

S Ogawa

22

1 reference

3 March 2018

J P Maciejewski

24

1 reference

3 March 2018

publication date

3 April 2015

1 reference

3 March 2018

published in

Leukemia

1 reference

3 March 2018

volume

29

1 reference

3 March 2018

issue

11

1 reference

3 March 2018

page(s)

2134-2142

1 reference

3 March 2018

The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation

cites work

1 reference

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 April 2017

1 reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 April 2017

1 reference

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 April 2017

1 reference

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 April 2017

1 reference

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 April 2017

1 reference

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

21 April 2017

1 reference

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 April 2017

1 reference

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 April 2017

1 reference

DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia

21 April 2017

1 reference

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 April 2017

1 reference

IDH1 and IDH2 mutations in gliomas

21 April 2017

1 reference

Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis

21 April 2017

1 reference

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.91

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.91

Frequent pathway mutations of splicing machinery in myelodysplasia

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.91

Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule

21 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Somatic SETBP1 mutations in myeloid malignancies

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Accurately identifying low-allelic fraction variants in single samples with next-generation sequencing: applications in tumor subclone resolution

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

A mechanistic overview of TET-mediated 5-methylcytosine oxidation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5821256

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

3 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.91

Metabolic quirks yield tumour hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.91

21 January 2018

Identifiers

DOI

10.1038/LEU.2015.91

1 reference

3 March 2018

Dimensions Publication ID

1043254453

0 references

OpenCitations bibliographic resource ID

3690013

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

3 March 2018

PubMed publication ID

25836588

1 reference

3 March 2018